DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix. DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research.
Type
Private
HQ
Richmond, US
Size (employees)
33 (est)+7%
DiaCarta is headquartered in Richmond, US
Report incorrect company information

Key People/Management at DiaCarta

Aiguo Zhang

Aiguo Zhang

President & CEO
Paul Okunieff

Paul Okunieff

CMO

DiaCarta Office Locations

DiaCarta has an office in Richmond
Richmond, US (HQ)
2600 Hilltop Dr
Show all (1)
Report incorrect company information

DiaCarta Financials and Metrics

Summary Metrics

Total Funding

$8 m

Latest funding size

$8 m

Time since last funding

3 years ago

Investors

DiaCarta's latest funding round in January 2015 was reported to be $8 m. In total, DiaCarta has raised $8 m
Report incorrect company information